SynthesisFrontiers in pharmacology2026
Cardioprotective effects of puerarin against myocardial ischemia-reperfusion injury: a preclinical systematic review and meta-analysis.
Synthesis in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Enhancement of content, purity and anti-myocardial ischemia-reperfusion injury activity of persimmon leaf flavonoids: Ultrasonic-assisted extraction, purification and related mechanism.Ultrasonics sonochemistry · 2026Article
- Precision immunomodulation of viral myocarditis: a spatiotemporal intervention paradigm based on smart biomaterials.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Myocardial ischemia-reperfusion injury (MIRI) remains a pivotal clinical conundrum in clinical cardiovascular practice, accounting for a substantial proportion of morbidity and mortality associated with cardiovascular disorders. Puerarin, a natural isoflavone derived from kudzu root, has shown promising cardioprotective potential in preclinical studies. Methods: Relevant studies were systematically searched in PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang, VIP Database, and Web of Science from inception to October 2025 for preclinical studies evaluating puerarin's effects on MIRI. Key outcome measures included myocardial infarction size, myocardial ischemic size, cardiac function parameters, myocardial injury markers, oxidative stress indicators, inflammatory cytokines, and the cardiomyocyte apoptosis index. Methodological quality was assessed using the SYRCLE risk-of-bias tool and GRADE tool, and meta-analyses were performed with RevMan 5.4.1 and STATA 18.0. Results: A total of 29 eligible studies were included. This meta-analysis showed that puerarin administration reduced the myocardial infarction size and myocardial ischemic size, improved cardiac systolic/diastolic function (e.g., increased LVEF, LVSP, and LVFS; decreased LVIDd and LVEDP), attenuated myocardial injury (decreased cTn-T, CK, CK-MB, and LDH levels), suppressed oxidative stress (elevated SOD and NO; reduced MDA), inhibited inflammatory responses (decreased TNF-α, IL-1β, and IL-6; increased GSH), and reduced cardiomyocyte apoptosis. Subgroup analysis indicated potential influences of the administration route, dosage, and animal body weight on partial outcomes. Conclusion: Preclinical evidence demonstrates that puerarin exerts cardioprotective effects against MIRI through multi-target mechanisms, including mitigating oxidative stress, suppressing inflammation, and inhibiting cardiomyocyte apoptosis. Despite consistent preclinical efficacy, well-designed clinical trials are needed to validate its translational potential and safety in humans. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251168227, identifier CRD420251168227.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.